Search

Your search keyword '"Goebel, Georg"' showing total 260 results
Start Over Author "Goebel, Georg" Publication Type Academic Journals
260 results on '"Goebel, Georg"'

3. Incidence and risk factors for anastomotic bile leakage in hepatic resection with bilioenteric reconstruction – A international multicenter study

Author

Braunwarth, Eva, Ratti, Francesca, Aldrighetti, Luca, Al-Saffar, Hasan A., D`Souza, Melroy A., Sturesson, Christian, Linke, Richard, Schnitzbauer, Andreas, Bodingbauer, Martin, Kaczirek, Klaus, Vagg, Daniel, Toogood, Giles, Ferraro, Daniele, Fusai, Giuseppe K., Diaz-Nieto, Rafael, Malik, Hassan, Hoogwater, Frederik J.H., Wagner, Doris, Kornprat, Peter, Fischer, Ines, Függer, Reinhold, Göbel, Georg, Öfner, Dietmar, and Stättner, Stefan

Published
2023
Full Text
View/download PDF

7. Early Screening for the Parkinson Variant of Multiple System Atrophy: A 6‐Item Score.

Author

Fanciulli, Alessandra, Stankovic, Iva, Avraham, Omer, Jecmenica Lukic, Milica, Ezra, Adi, Leys, Fabian, Goebel, Georg, Krismer, Florian, Petrovic, Igor, Svetel, Marina, Seppi, Klaus, Kostic, Vladimir, Giladi, Nir, Poewe, Werner, Wenning, Gregor K., and Gurevich, Tanya

Subjects
MULTIPLE system atrophy, PARKINSON'S disease, ORTHOSTATIC hypotension, OVERACTIVE bladder, SENSITIVITY & specificity (Statistics)
Abstract

Background: A 4‐item score based on ≥2 features out of orthostatic hypotension, overactive bladder, urinary retention and postural instability was previously shown to early distinguish the Parkinson‐variant of multiple system atrophy (MSA‐P) from Parkinson's disease (PD) with 78% sensitivity and 86% specificity. Objectives: To replicate and improve the 4‐item MSA‐P score. Methods: We retrospectively studied 161 patients with early parkinsonism [ie, ≤2 years disease duration or no postural instability, aged 64 (57; 68) years, 44% females] and a diagnosis of clinically established MSA‐P (n = 38) or PD (n = 123) after ≥24 months follow‐up. Results: The 4‐item MSA‐P score had a 92% sensitivity and 78% specificity for a final MSA‐P diagnosis. By including dopaminergic responsiveness and postural deformities into a 6‐item score (range: 0–6), reaching ≥3 points at early disease identified MSA‐P patients with 89% sensitivity and 98% specificity. Conclusions: The 6‐item MSA‐P score is a cost‐effective tool to pinpoint individuals with early‐stage MSA‐P. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Development and Validation of a Prognostic Model to Predict Overall Survival in Multiple System Atrophy.

Author

Eschlboeck, Sabine, Goebel, Georg, Eckhardt, Christine, Fanciulli, Alessandra, Raccagni, Cecilia, Boesch, Sylvia, Djamshidian, Atbin, Heim, Beatrice, Mahlknecht, Philipp, Mair, Katherina, Nachbauer, Wolfgang, Scherfler, Christoph, Stockner, Heike, Poewe, Werner, Seppi, Klaus, Kiechl, Stefan, Wenning, Gregor, Krismer, Florian, Barone, Paolo, and Pellecchia, Maria Teresa

Subjects
*ORTHOSTATIC hypotension, *OVERALL survival, *PROGNOSTIC models, *MULTIPLE system atrophy, *REGRESSION analysis, *MODEL validation, *PROGNOSIS
Abstract

Background: Multiple system atrophy (MSA) is a devastating disease characterized by a variable combination of motor and autonomic symptoms. Previous studies identified numerous clinical factors to be associated with shorter survival. Objective: To enable personalized patient counseling, we aimed at developing a risk model of survival based on baseline clinical symptoms. Methods: MSA patients referred to the Movement Disorders Unit in Innsbruck, Austria, between 1999 and 2016 were retrospectively analyzed. Kaplan–Meier curves and multivariate Cox regression analysis with least absolute shrinkage and selection operator penalty for variable selection were performed to identify prognostic factors. A nomogram was developed to estimate the 7 years overall survival probability. The performance of the predictive model was validated and calibrated internally using bootstrap resampling and externally using data from the prospective European MSA Study Group Natural History Study. Results: A total of 210 MSA patients were included in this analysis, of which 124 patients died. The median survival was 7 years. The following clinical variables were found to significantly affect overall survival and were included in the nomogram: age at symptom onset, falls within 3 years of onset, early autonomic failure including orthostatic hypotension and urogenital failure, and lacking levodopa response. The time‐dependent area under curve for internal and external validation was >0.7 within the first 7 years of the disease course. The model was well calibrated showing good overlap between predicted and actual survival probability at 7 years. Conclusion: The nomogram is a simple tool to predict survival on an individual basis and may help to improve counseling and treatment of MSA patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

24. The natural history of multiple system atrophy: a prospective European cohort study

Author

Wenning, Gregor K, Geser, Felix, Krismer, Florian, Seppi, Klaus, Duerr, Susanne, Boesch, Sylvia, Köllensperger, Martin, Goebel, Georg, Pfeiffer, Karl P, Barone, Paolo, Pellecchia, Maria Teresa, Quinn, Niall P, Koukouni, Vasiliki, Fowler, Clare J, Schrag, Anette, Mathias, Christopher J, Giladi, Nir, Gurevich, Tanya, Dupont, Erik, Ostergaard, Karen, Nilsson, Christer F, Widner, Håkan, Oertel, Wolfgang, Eggert, Karla Maria, Albanese, Alberto, del Sorbo, Francesca, Tolosa, Eduardo, Cardozo, Adriana, Deuschl, Günther, Hellriegel, Helge, Klockgether, Thomas, Dodel, Richard, Sampaio, Cristina, Coelho, Miguel, Djaldetti, Ruth, Melamed, Eldad, Gasser, Thomas, Kamm, Christoph, Meco, Giuseppe, Colosimo, Carlo, Rascol, Olivier, Meissner, Wassilios G, Tison, François, and Poewe, Werner

Published
2013
Full Text
View/download PDF

25. Prospective Follow-Up of Patients with Acute Hepatitis C Virus Infection in Brazil

Author

Lewis-Ximenez, Lia L., Lauer, Georg M., zur Wiesch, Julian Schulze, de Sousa, Paulo Sergio Fonseca, Ginuino, Cleber F., Paranhos-Baccalá, Gláucia, Ulmer, Hanno, Pfeiffer, Karl P., Goebel, Georg, Pereira, João Luiz, de Oliveira, Jaqueline Mendes, Yoshida, Clara Fumiko Tachibana, Lampe, Elisabeth, Velloso, Carlos Eduardo, Pinto, Marcelo Alves, Coelho, Henrique Sergio, Almeida, Adilson José, Fernandes, Carlos Augusto, Kim, Arthur Y., and Strasak, Alexander M.

Published
2010

28. Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules.

Author

Goebel, Georg L., Qiu, Xiaqiu, and Wu, Peng

Subjects
*MOLECULES, *KINASE inhibitors, *DRUG target, *SMALL molecules, *KINASES
Abstract

Kinases are among the most successful drug targets. To date, 72 small-molecule kinase inhibitors (SMKIs) have been approved by the US FDA, together with ~500 SMKIs in clinical trials. Although the topic has been heavily reviewed in recent years, an overview that focused on the currently approved SMKIs in combination with the emerging kinase-targeting bifunctional molecules is absent. Herein, we first provide an updated overview of the approved SMKIs, with an emphasis on their binding modes, classified in groups of type I and II ATP-competitive inhibitors, type III and IV allosteric inhibitors, and covalent inhibitors. We then highlight the novel chemical modalities in kinase targeting by using different types of proximity-inducing bifunctional molecules for kinase degradation and modifications. Overview of the 72 FDA-approved small-molecule kinase inhibitors (SMKIs) classified by binding modes. The 72 SMKIs include a majority of type I and type II ATP-competitive inhibitors, four type III allosteric MEK inhibitors, one type IV allosteric ABL inhibitor, and eight covalent inhibitors. Proximity-inducing bifunctional molecules are emerging new chemical modalities that hold tremendous opportunities in kinase-targeting research. Kinase degradation occurs via PROTACs, stabilization via DUBTACs, phosphorylation via PHICS, and kinase dephosphorylation via PhoRCs. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

40. MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.

Author

Heugenhauser, Johanna, Galijasevic, Malik, Mangesius, Stephanie, Goebel, Georg, Buchroithner, Johanna, Erhart, Friedrich, Pichler, Josef, Widhalm, Georg, Stockhammer, Günther, Iglseder, Sarah, Freyschlag, Christian F., Oberndorfer, Stefan, Bordihn, Karin, von Campe, Gord, Czech, Thomas, Surböck, Birgit, Urbanic Purkart, Tadeja, Marosi, Christine, Felzmann, Thomas, and Nowosielski, Martha

Subjects
GLIOMA treatment, IMMUNE checkpoint inhibitors, MAGNETIC resonance imaging, RETROSPECTIVE studies, TREATMENT effectiveness, PROGRESSION-free survival, IMMUNOTHERAPY, THERAPEUTICS
Abstract

Simple Summary: In order to compare responses to different therapies among clinical trials and to differentiate between therapy-induced changes and true tumor progression, reliable response parameters are crucial. With the advent of targeted and immunologic treatments, several assessment tools have been proposed. In this post hoc analysis we compared assessment criteria according to MacDonald, RANO, mRANO, iRANO as well as Vol-RANO and Vol-mRANO in patients with newly diagnosed glioblastoma treated with standard of care (SOC) ± tumor lysate-charged autologous dendritic cells (Audencel). We found that the best correlation between progression-free survival (PFS) and overall survival (OS) was seen for mRANO and Vol-mRANO. Interestingly, iRANO was not superior for predicting OS in patients treated with Audencel. Introduction: In this post hoc analysis we compared various response-assessment criteria in newly diagnosed glioblastoma (GB) patients treated with tumor lysate-charged autologous dendritic cells (Audencel) and determined the differences in prediction of progression-free survival (PFS) and overall survival (OS). Methods: 76 patients enrolled in a multicenter phase II trial receiving standard of care (SOC, n = 40) or SOC + Audencel vaccine (n = 36) were included. MRI scans were evaluated using MacDonald, RANO, Vol-RANO, mRANO, Vol-mRANO and iRANO criteria. Tumor volumes (T1 contrast-enhancing as well as T2/FLAIR volumes) were calculated by semiautomatic segmentation. The Kruskal-Wallis-test was used to detect differences in PFS among the assessment criteria; for correlation analysis the Spearman test was used. Results: There was a significant difference in median PFS between mRANO (8.6 months) and Vol-mRANO (8.6 months) compared to MacDonald (4.0 months), RANO (4.2 months) and Vol-RANO (5.4 months). For the vaccination arm, median PFS by iRANO was 6.2 months. There was no difference in PFS between SOC and SOC + Audencel. The best correlation between PFS/OS was detected for mRANO (r = 0.65) and Vol-mRANO (r = 0.69, each p < 0.001). A total of 16/76 patients developed a pure T2/FLAIR progressing disease, and 4/36 patients treated with Audencel developed pseudoprogression. Conclusion: When comparing different response-assessment criteria in GB patients treated with dendritic cell-based immunotherapy, the best correlation between PFS and OS was observed for mRANO and Vol-mRANO. Interestingly, iRANO was not superior for predicting OS in patients treated with Audencel. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

50. Screening for Open Spina Bifida in a Routine Clinical Setting at the First-Trimester Scan: A Prospective Multicentre Cohort Study.

Author

Tiechl, Johanna, Abdel Azim, Samira, Leitner, Katharina, Berger, Astrid, Mutz-Dehbalaie, Irene, Goebel, Georg, and Scheier, Matthias

Abstract

Objective: The aim of this study was to investigate the performance of screening for open spina bifida (OSB) integrated into the routine first-trimester screening. Method: This is a prospective multicentre study of 4,755 women undergoing first-trimester ultrasound scans over a 4-year period. Measurements of the brainstem (BS) diameter and brainstem-to-occipital-bone (BSOB) distance were performed. The cisterna magna (CM) was measured in the tilted axial view. Results: Pregnancy outcome data were available for 4,658 fetuses included in this study. There were 5 fetuses with OSB, and in all of them, the BS/BSOB ratio and the CM measurements were abnormal. The sensitivity and specificity of a BS/BSOB ratio >1 were 100%. The sensitivity of a CM width <5th centile was 100%, and the specificity was 95.1%. In 4.6% of cases, the BS/BSOB ratio was between the 95th percentile and 1. In 87.1% of these cases, the CM was normal, and 12.9% had a CM below the 5th percentile. Conclusion: Screening for OSB is feasible in routine first-trimester scans. The BS/BSOB ratio shows a very good sensitivity and specificity. In cases with near-normal values for the BS/BSOB ratio, the CM width might be helpful for further assessment. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results